CoRegen is pioneering a novel approach to cancer therapy by focusing on the immune system's ability to target and destroy cancer cells. The company has identified a specific gene within T regulatory cells (T reg) that, when engineered, enhances the immune response against various types of cancer. This innovative strategy aims to treat multiple aggressive cancers, including triple-negative breast cancer, lung cancer, and glioblastoma, while minimizing toxicity, inflammation, and off-target effects. CoRegen's collaboration with Baylor College of Medicine provides access to advanced research facilities and a team of experts, bolstering their efforts in developing effective cancer treatments.

In addition to their cancer therapies, CoRegen has a robust patent portfolio that includes methods for engineering T reg cells and small molecule inhibitors that block cancer cell growth while promoting immune system activity. Their research also extends to potential applications in treating non-malignant diseases, such as heart attack and stroke, where their SRC-3 mechanism has shown promise in preclinical studies. This dual focus on both oncology and broader therapeutic applications positions CoRegen as a forward-thinking entity in the field of regenerative medicine and cancer therapy.

United States

CoRegen is leveraging its groundbreaking master gene regulator platform to develop a broad range of therapeutics capable of controlling numerous genes throughout the body, with lead indications in solid tumors.

CoRegen

Company Details